Back to Resource Center

Sexual Satisfaction Results With the Vaginal pH Modulator From the Phase 3 AMPOWER Study

Sexual Satisfaction Results With the Vaginal pH Modulator From the Phase 3 AMPOWER Study

View Journal Article

The Journal of Sexual Medicine has published data from EVFM’s Phase 3 AMPOWER registration trial demonstrating that 88.7% of women using Phexxi improved or maintained their sex life. “Phexxi offered the women in this study a non-hormonal, woman-controlled, on-demand contraceptive gel that clearly provided a unique set of positive benefits on their sexual health and enjoyment,” said Dr. Todd Chappell, a lead investigator on the AMPOWER study and practicing obstetrician and gynecologist.

March 2022

Click to view Journal Article

Click for full info +

Full Info:


Resource Type:

Journal Article

Authors:

Michael A. Thomas, MD, Robert Morlock, PhD, Clint Dart, MS, and Brandon Howard, PhD

Health Risks(s):

  • Unintended Pregnancy

Product type(s):

  • MPTs
  • VaginalCream

Topic(s):

  • MPTs
  • Development
  • Reproductive Health
  • Social

Region(s)

  • United States

URL of resource:

https://theimpt.org/wp/wp-content/uploads/2022/04/2202.04.19_EVFM-Announces-Publication-of-Phexxi-Sexual-Satisfaction-Data.pdf

Back to Resource Center